These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 29495116

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V.
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W.
    BMC Res Notes; 2015 Oct 26; 8():609. PubMed ID: 26502722
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Ippolito D, Querques G, Pecorelli A, Talei Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S.
    J Comput Assist Tomogr; 2019 Oct 26; 43(2):206-213. PubMed ID: 30407241
    [Abstract] [Full Text] [Related]

  • 8. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.
    Eilard MS, Andersson M, Naredi P, Geronymakis C, Lindnér P, Cahlin C, Bennet W, Rizell M.
    BMC Cancer; 2019 Jun 11; 19(1):568. PubMed ID: 31185950
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T, Palmer DH, Cheng AL, Hocke J, Loembé AB, Yen CJ.
    Liver Int; 2017 Jul 11; 37(7):1047-1055. PubMed ID: 28066978
    [Abstract] [Full Text] [Related]

  • 11. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
    Lee PC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lee MH, Hou MC, Lee FY, Lin HC, Huang YH.
    Liver Int; 2018 Feb 11; 38(2):321-330. PubMed ID: 28736952
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
    Cancer; 2012 Jan 01; 118(1):147-56. PubMed ID: 21713764
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma.
    Donati OF, Do RK, Hötker AM, Katz SS, Zheng J, Moskowitz CS, Beattie C, Brown KT.
    Eur Radiol; 2015 Sep 01; 25(9):2779-88. PubMed ID: 25850892
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
    Bargellini I, Scionti A, Mismas V, Masi G, Vivaldi C, Bartolozzi C, Sacco R.
    Oncology; 2014 Sep 01; 86(4):191-8. PubMed ID: 24800837
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.